A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy

Rashmi Jadon\textsuperscript{1,2*}, Emma Higgins\textsuperscript{1}, Louise Hanna\textsuperscript{1}, Mererid Evans\textsuperscript{1}, Bernadette Coles\textsuperscript{3} and John Staffurth\textsuperscript{1,4}

Abstract

Background: Advanced pelvic radiotherapy techniques aim to reduce late bowel toxicity which can severely impact the lives of pelvic cancer survivors. Although advanced techniques have been largely adopted worldwide, to achieve their aim, knowledge of which dose-volume parameters of which components of bowel predict late bowel toxicity is crucial to make best use of these techniques. The rectum is an extensively studied organ at risk (OAR), and dose-volume predictors of late toxicity for the rectum are established. However, for other components of bowel, there is a significant paucity of knowledge. The Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) reviews recommend dose-volume constraints for acute bowel toxicity for peritoneal cavity and bowel loops, although no constraints are recommended for late toxicity, despite its relevance to our increasing number of survivors. This systematic review aims to examine the published literature to seek dose-volume predictors and constraints of late bowel toxicity for OARs (apart from the rectum) for use in clinical practice.

Methods: A systematic literature search was performed using Medline, Embase, Cochrane Library, Web of Science, Cinahl and Pubmed. Studies were screened and included according to specific pre-defined criteria. Included studies were assessed for quality against QUANTEC-defined assessment criteria.

Results: 101 studies were screened to find 30 relevant studies. Eight studies related to whole bowel, 11 to small bowel, and 21 to large bowel (including 16 of the anal canal). The anal canal is an important OAR for the development of late toxicity, and we recommend an anal canal Dmean <40Gy as a constraint to reduce late incontinence. For other components of bowel (sigmoid, large bowel, intestinal cavity, bowel loops), although individual studies found statistically significant parameters and constraints these findings were not corroborated in other studies.

Conclusions: The anal canal is an important OAR for the development of late bowel toxicity symptoms. Further validation of the constraints found for other components of bowel is needed. Studies that were more conclusive included those with patient-reported data, where individual symptom scores were assessed rather than an overall score, and those that followed statistical and endpoint criteria as defined by QUANTEC.
Background

Pelvic radiotherapy is used to treat approximately 17,000 patients per year in the UK with urological, gynaecological and colorectal malignancies [1]. For a significant proportion of these patients, pelvic radiotherapy improves survival outcomes. For others, it reduces the risk of pelvic recurrences, which can both cause distressing symptoms and be difficult to manage.

Although contributing to the cure of many pelvic cancer survivors, pelvic radiotherapy is associated with late toxicity, in particular late bowel toxicity. Serious life-threatening toxicity such as bowel obstruction, fistulae and bleeding requiring transfusion occur in 4–10% of patients 5–10 years after treatment [2]. Furthermore, an important consideration for the growing number of survivors of pelvic cancers is that 50% of patients report late bowel toxicity symptoms which adversely affect their quality of life after pelvic radiotherapy.

Late bowel toxicity is generally attributed to radiation to bowel and rectum and these are considered the organs at risk (OARs). Advanced radiotherapy techniques for pelvic treatments are continually evolving, with the aim of reducing dose to these OARs. However, to determine whether the dose reductions achieved by these techniques are likely to translate into reduced toxicity for patients requires detailed knowledge of the dose-volume parameters and constraints for these OARs. Once dose-volume constraints are known these can be used to limit the risk of toxicity and potentially allow safe dose escalation with modern delivery techniques.

In 2010 the Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarised the available dose-volume data for bowel toxicity, with one review focussing on rectum and the other on stomach and bowel. For rectum, an extensively studied OAR, QUANTEC reviewed a large amount of high-quality data and dose-volume constraints for rectum for acute and late toxicity were recommended [3]. These are commonly incorporated into radiotherapy protocols in clinical practice.

However, for bowel there was a relative paucity of data. QUANTEC reviewed data from six papers which examined the dose-volume relationship of bowel with acute bowel toxicity only [4]. For late bowel toxicity, there was no detailed dose-volume relationship analysis described. Studies mentioned were trial data detailing the incidence of late bowel toxicity at the dose-fractionations used within each trial, though no specific dose-volume predictors can be derived from this information.

The QUANTEC reviewers suggest that the constraints identified for acute bowel toxicity may be applied for late bowel toxicity however clarify that “this correlation is not established”. Further, although QUANTEC examined the peritoneal cavity and small bowel loops as OARs, the potential of other bowel components as OARs for bowel toxicity such as sigmoid, duodenum, ileum and anal canal are not detailed.

In a separate paper by Jackson et al., QUANTEC [5] highlighted issues which hinder the development of dose-volume constraints and the pooling of results from different studies, including variations in toxicity endpoint definition, statistical standards, and anatomical definitions of OARs. They recommended several criteria to assess the quality of future dose-volume studies and to facilitate meta-analysis of these studies.

With reduction of late bowel toxicity being a prime aim of advanced pelvic radiotherapy techniques, the lack of clear dose-volume constraints in this setting has been acknowledged and more studies have been reported. This study aims to systematically review published studies examining the dose-volume predictors of all components of bowel (excluding rectum) for late bowel toxicity, including a quality assessment of these studies from criteria derived from QUANTEC.

From this review we aim to determine the clinically useful dose-volume constraints for late bowel toxicity which can guide protocols for advanced pelvic radiotherapy techniques.

Methods

Information sources and search strategy

A systematic search was carried out using Medline, Pre-medline, Embase, Pubmed and Web of Science on 15th October 2013; Updated searches were performed on 10th November 2014, 3rd September 2015 and 1st May 2017 to ensure all new literature was included. Thesaurus and natural language terms around the concepts of “radiotherapy, radiotherapy injuries, side effects, toxicity, intestines bowel, dose, dose fractionation, dose response relationship” were identified for each database. Duplicate references were removed.

Study selection

Eligible studies were English language studies, involving human adult patients treated for any gastrointestinal, urological or gynaecological malignancies with external beam radiotherapy. Studies correlating the dose-volume relationship of any component of bowel from duodenum to anal canal with late bowel toxicity were included, apart from those focussed on the rectum, given that it has already been extensively studied as an OAR. Late toxicity was defined as more than 3 months from completion of radiotherapy.

Excluded studies were review articles and letters, studies involving brachytherapy only, or stereotactic body radiotherapy. Both full text papers and conference
abstracts were considered, however studies with insufficient methodological detail to be able to repeat the method on an independent sample of patients were excluded.

All abstracts were independently screened by two reviewers (RJ, EH) for inclusion. Full papers of abstracts were acquired and further assessed for eligibility, with any discrepancies discussed between the two reviewers. The reference lists of all the included papers were hand-searched for additional references.

Data extraction and synthesis of results
Bowel can be defined in several different ways and for the purpose of this review studies were divided into those looking at the whole bowel (including bowel loops and peritoneal cavity), small bowel (and its components) and large bowel (and its components). For each included study the number of patients, proportion with the toxicity, tumour site, OAR studied, toxicity definition, treatment details and key findings were tabulated.

Furthermore, the recommendations from QUANTEC [5] on quality of dose-volume studies were reviewed, and those criteria that can be applied to this subject were selected (see Table 1). Each included study was assessed for quality against these statistical and endpoint criteria.

### Table 1 Statistical and Endpoint Considerations from QUANTEC [5]

| Statistical considerations |
|-----------------------------|
| 1 Basic statistical data provided on incidence of toxicity |
| - Both number of subjects and number of events should be reported |
| - If an estimate of incidence is given the standard error should be supplied |
| 2 Numerical labeling of response histogram – if into groups eg. quartiles must state number of patients in each quartile |
| 3 When predictive models are correlated with complications parameter estimates must be stated with their standard error |
| 4 Complication rates associated with constraints must be reported |
| 5 "Goodness of fit" to be reported such as Chi-squared |
| 6 Discriminator statistics reported such as receiver operating characteristic curves |
| 7 Full organ volumes (rather than partial) should be used |
| - If this is not possible absolute volumes should be used or a standard method of normalization |
| - A clear statement of organ volume definition should be given |

Toxicity Endpoint considerations

| 1 Symptom-specific information rather than a portmanteau endpoint (eg. RTOG gr 2) should be used |
| 2 Consideration that symptoms may be attributed to pre-radiotherapy co-morbidities |
| 3 Patient-reporting of symptoms may be important |

Results
Outcomes of the systematic search are shown in Fig. 1. Overall, 30 studies involving a total of 5126 patients were included as detailed in Table 2. Twenty-one studies included patients with prostate cancer, 6 with gynaecological cancers (cervical and endometrial), and 2 each included bladder and pancreatic cancers. Most studies (n = 18) included less than 100 patients, with 9 studies having less than 50 patients included.

Table 3 details studies for whole and small bowel, and Table 4 those for large bowel. In each table the final two columns indicate the quality assessment criteria of statistical and endpoint considerations as defined in Table 1. If a specific criterion is met its number is noted in the column.

Whole bowel
Eight papers (including 445 patients) examined the dose-volume relationship of whole bowel either using bowel loops or intestinal/peritoneal cavity as detailed in Table 3.

Peritoneal cavity
Late bowel toxicity was associated with low doses to the peritoneal cavity (V10–30Gy) in 2 studies. Mouuttet-Audouard et al. [6] found, in 37 cervical cancer patients, an association between “bigger volumes” of bowel receiving 10–30Gy and grade 1–3 Common Terminology Criteria Adverse Events (CTCAE) toxicity, although specific cut-offs were not reported. Deville et al. [7] found that peritoneal cavity volume and V20 were both associated with grade 1 Radiation Therapy Oncology Group (RTOG) toxicity. Again no constraints were derived.

Bowel loops
Two studies [8, 9] investigated bowel loops as an OAR for late toxicity, both with an identical definition of bowel loops. Guerrero-Urbano et al., in 79 patients who had their prostate and pelvic nodes treated, found V40, V45 and V60 bowel loops to be predictive of late grade 2 RTOG-graded diarrhoea. They suggested constraints of V40 < 124 cc, V45 < 71 cc and V60 < 0.5 cc to reduce grade 2 RTOG toxicity, although no complication rates associated with these constraints are detailed. McDonald et al. in their study of 47 bladder cancer patients suggested constraints to reduce the risk of grade ≥2 RTOG toxicity to less than 25% (V30 < 178 cc; V40 < 151 cc; V45 < 139 cc; V60 < 98 cc and V65 < 40 cc), although it must be noted that only 3 patients within this study had grade 2 toxicity.

Small bowel and its components
Eleven studies (including 1401 patients) were included in this section, with 6 studies examining small bowel
and 4 examining the duodenum, as detailed in Table 3. No papers investigating the ileum or jejunum were found.

Small bowel
2 of 6 studies found positive correlations with late bowel toxicities and small bowel volume parameters in cervical cancer patients. However, the positive parameters were different between the studies, with Isohashi et al. \cite{10} recommending a V40 < 340 cc, and Chopra et al. \cite{11} recommending a V15 < 275 cc. Lind et al. \cite{12} found that a mean small bowel dose >50Gy was of significance, however could not clarify whether toxicity was linked specifically to small bowel, sigmoid or anal sphincter dose, making these results difficult to interpret.

Duodenum
3 of 4 studies found positive correlations between dose-volume parameters and duodenal toxicity. Two studies found V55 to be an important predictor, though with differing constraints. Kelly et al., in 106 pancreatic patients recommending a V55 < 1 cc \cite{13} and Verma et al. in 105 gynaecological patients recommending a V55 < 15 cc \cite{14}. Huang et al. \cite{15} found V25 to be the significant predictor for pancreatic cancer patients treated with concurrent gemcitabine; with a V25 < 45% toxicity rates were 8%, above this constraint toxicity was 48%. Investigation of individual duodenal segments did not reveal any positive findings \cite{16}.

Large bowel and its components
21 studies (including 5006 patients) were included in this section (see Table 4), with 2 examining large bowel, 3 examining sigmoid and 16 studies examining the anal canal/sphincter region.

Large bowel and sigmoid Colon
Chopra et al. \cite{11} found on multivariate analysis that V15 of large bowel was associated with grade 3 CTCAE toxicity ($p < 0.03$), and recommended with the use of the
| Author       | Year | Cancer site                  | No of pts | Pts with tox OAR studied | Toxicity score used | RT Type       | Primary RT Dose (Gy/#) | Pelvic RT Dose (Gy/#) | Concurrent chemo use |
|--------------|------|------------------------------|-----------|--------------------------|---------------------|---------------|-----------------------|---------------------|----------------------|
| Adkison      | 2012 | Prostate                    | 53        | small bowel              | CTCAE v3.0          | IMRT          | 70/28                 | 56/28               | no                   |
| al-Abany     | 2005 | Prostate                    | 65        | anal sphincter region    | Own questionnaire   | 3D            | 70.2/39               | NS                  | no                   |
| Alsadius     | 2012 | Prostate or prostatic bed   | 403       | anal sphincter region    | Own questionnaire   | 3D            | 70/35                 | NS                  | no                   |
| Buettner     | 2012 | Prostate                    | 388       | anal canal               | Common grading scheme | 3D         | 64/32 or 74/37        | NS                  | no                   |
| Chopra       | 2014 | Cervix (post-op)            | 71        | small bowel, large bowel | CTCAE v3.0          | IG-MRT (46); 3D (25) | 50/25 | 50/25 | 63/71 cisplatin       |
| DeVille      | 2010 | Prostate                    | 30        | intestinal cavity        | RTOG                | IMRT          | 79.2/44               | 45/25               | no                   |
| DeVille      | 2012 | Prostatic bed               | 36        | intestinal cavity        | RTOG                | IMRT          | 70.2/39               | 45/25               | no                   |
| Ebert        | 2015 | Prostate                    | 754       | Symptom specific         | Anal canal          | LENT-SOMA IMRT | 66–78/33–38          | NS                  | no                   |
| Fokdal       | 2005 | Prostate or bladder         | 71        | Symptom specific         | small bowel         | LENT-SOMA Conformal | 60/30 (bladder) 69.6/35 (prostate) | 48-60Gy bladder; NS for prostate | no |
| Fonteyne     | 2007 | Prostate                    | 241       | Symptom specific         | small bowel, sigmoid | RTOG and “RLIT” IMRT | 74/37–80/40 | 45                   |
| Green        | 2015 | Prostate or prostatic bed   | 73        | Intestinal cavity        | CTCAE v4.0 IMRT/VMAT | 61–79.2 | 45                   | no |
| Guerrero-Urbano | 2010 | Prostate & Pelvic nodes     | 79        | bowel loops              | RTOG diarrhoea & LENT SOMA diarrhoea IMRT | 70/35 | 50/35 or 55/35 | no |
| Huang        | 2011 | Pancreas                    | 46        | duodenum                 | CTCAE v4.0          | 3D or IMRT | 42/15                | 42/15; 36/15; 38/19 | Gemcitabine; 18 pts. erlotinib in addition |
| Isohashi     | 2013 | Cervix (post-op)            | 97        | peritoneal cavity, small and large bowel | RTOG/EORTC 2D or 3D | 50/25 | 50/25 | All nedaplatin |
| Kelly        | 2013 | Pancreas                    | 106       | duodenum                 | CTCAE v4.0          | 3D or IMRT | 50.4/28 (78pts); 57.5–75.4 in 28–39# (28pts); 50.4/28 (78pts); 57.5–75.4 in 28–39# (28pts) | Gemcitabine 5-FU or capecitabine +/- cetuximab or erlotinib |
| Koper        | 2004 | Prostate                    | 266       | anal canal               | RTOG (simplified) Symptom questionnaire | 3D or 2D | 66/33 | NS | no |
| Lind         | 2016 | Cervical or Endometrium     | 519       | Anal sphincter, small bowel, sigmoid | Own questionnaire (defecation into clothing without forewarning) | 2D or 3D | 40–46 (endometrium) or 55–70 (cervix) | NS | Not stated |
Table 2: All included studies (Continued)

| Study                          | Year | Location  | V15  | V30  | V40  | Symptom/Region       | Questionnaire | Technology | Toxicity | Fraction | NS  | Cut-off | Adjuvant  |
|--------------------------------|------|-----------|------|------|------|----------------------|---------------|------------|----------|----------|------|---------|-----------|
| Mavroidis                      | 2005 | Prostate  | 65   | Symptom specific | anal sphincter | Own questionnaire | 3D           | 70.2/39    | NS       | no       |     |         |           |
| Mcdonald                       | 2015 | Bladder   | 47   | 10    |      | bowel loops          | RTOG          | 3D         | 64/32    | 64/32    | 21   | received | 5-Flu/MMC |
| Mouttet-Audouard               | 2015 | Cervical  | 37   | 8     |      | Small bowel [defined as peritoneal cavity], sigmoid | CTCAE v4.0    | IMRT (tomotherapy) | 60/28    | 50/28    | Cisplatin |
| Peeters [21]                   | 2006 | Prostate  | 641  | 146   |      | Anal wall            | RTOG/EORTC plus 5 specified symptoms | 3D (41 pts. had IMRT boost) | 68/34 or 78/39 | NS       | no       |     |         |           |
| Peeters [28]                   | 2006 | Prostate  | 368  | 32    |      | Anal wall            | Incontinence (no specific questionnaire) | 3D (22 pts. had boost) | 68/34 or 78/39 | NS       | no       |     |         |           |
| Poovu [16]                     | 2013 | Cervix & Endometrium (+ PA nodes) | 46   | 3     |      | peritoneal cavity, small bowel, duodenal segments | CTCAE v4.0 | IMRT | 45/25 & PAN boost 50–65 (33 pts) | 45/25 & PAN boost 50–65 (33 pts) | 24 received cisplatin |
| Smeenk [26]                    | 2012 | Prostate  | 48   | 21    |      | Anal sphincter muscles | Presence of frequency, urgency and incontinence | 3D (n = 43, IMRT (n = 5) | 67.5/27 or 70/28 | NS       | no       |     |         |           |
| Smeenk [22]                    | 2012 | Prostate  | 36   | 23    |      | Anal wall             | Late RILIT score: urgency, incontinence, frequency | 3D           | 67.5/27 or 70/28 | NS       | no       |     |         |           |
| Taussky [37]                   | 2003 | Prostate  | 73   | unclear | anal canal | UCLA, FACT-P and EORTC. QLQ-PR25 | 3D           | 66.6–72/37–40 | NS       | no       |     |         |           |
| Thor [29]                      | 2015 | Prostate  | 212  | Symptom specific | Anal sphincter | Own questionnaire with 19 descriptors for 4 symptoms | 3D           | 70–78Gy    | NS       | no       |     |         |           |
| Verma [30]                     | 2014 | Cervix & Endometrium | 105  | 9     | duodenum | RTOG and endoscopic findings | IMRT | 45–50 (60–66Gy boost) | 45–50 (60–66 boost) | 58 pts. platinum agents |
| Vordermark [23]                | 2003 | Prostate or prostatic bed | 44   | 14% severe incontinence | anal canal | 10 question continence questionnaire | 3D           | 58–72/29–36 | NS       | No       |     |         |           |
| Yeoh [24]                      | 2016 | Prostate  | 106  | 72%   |      | Anal wall            | LENT-SOMA total score | 3D           | 66–74/433–4 | NS       | no       |     |         |           |

Abbreviations: Pts Patients, OAR Organs at risk, RT Radiotherapy, Gy Gray, # Fraction, NS Not stated, CTCAE Common terminology criteria for adverse events, RTOG Radiation therapy oncology group, LENT-SOMA Late Effects of Normal Tissue – Subjective Objective Management Analytical, RILIT Radiation induced late intestinal toxicity, EORTC European Organisation for Research and Treatment of Cancer, IG-IMRT Image-guided intensity modulated radiotherapy, IMRT Intensity modulated radiotherapy, VMAT Volumetric modulated arc therapy, PA nodes Para-aortic nodes, pts Patients

Constraints: V15 < 250 cc, V30 < 100 cc and V40 < 90 cc grade 3 toxicity could reduce from 26.7 to 5.4%.

For the sigmoid colon Fonteyne et al. [17] found in 241 prostate patients that sigmoid V40 was associated with grade 1 diarrhoea and blood loss; they recommended V40 < 10% and V30 < 16% to avoid grade 1–2 diarrhoea. Mouttet-Aldouard et al. [6] also found sigmoid V30–40Gy to be significantly correlated (p < 0.006) with “digestive toxicity” although no specific cut-offs were defined.

Anal canal
15 of 16 studies had positive findings relating dose-volume parameters and Normal Tissue Complication Probability (NTCP) models of the anal canal/sphincter to late toxicity. Most defined the anal canal as the distal 3 cm of rectum.

Dmean
5 studies [18–22] found Dmean anal canal or anal sphincter region to be most predictive of toxicity, 4 of
| Author             | OAR studied | OAR defined | Toxicity definition | Pts with toxicity | Significant findings                                                                 | Quality Assessment | Statistical criteria met (1–7) | Endpoint criteria met (1–3) |
|--------------------|-------------|-------------|---------------------|------------------|--------------------------------------------------------------------------------------|-------------------|-------------------------------|-----------------------------|
| Deville [7]        | Intestinal cavity | Intestinal cavity below L4–5 | RTOG Gr ≥ 1 | 5/36 (14%) | Toxicity associated with total volume & V20. No constraints specified. | 1,7               | (n/a: 2–6)                   | None                         |
| Mouttet-Audouard [6] | “Small bowel” (outlined as abdominal cavity hence included in this section) | Entire abdominal cavity including all possible organ locations to iliac crests or D12/L1 | CTCAE v4.0 Gr1–3 = diarrhoea or “whole digestive toxicity” (diarrhoea, gastritis, bleeding, pain, incontinence) | 8/37 (21.6%) | Larger volumes of bowel receiving 10–30Gy associated with diarrhoea & whole digestive toxicity. (No constraints specified) “Whole digestive toxicity” associated with many parameters including D20%–D95%. | 1,7               | (n/a: 2–6)                   | 2                           |
| Green [36]         | Intestinal cavity | Not stated | CTCAE v4.0 | 9 (12%) | No dose-volume relationship found. | 1 (n/a: 2–6)       | 2                             |                             |
| Deville [31]       | Intestinal cavity | Large & small bowel below L4–5 | RTOG Gr ≥ 2 | 2/30 (6%) | No dose-volume relationship found. | 1,7               | (n/a: 2–6)                   | None                         |
| Isohashi [10]      | Peritoneal cavity | Volume surrounding small bowel loops to edge of peritoneum excluding bladder & rectum | RTOG/EORTC Gr ≥ 2 | 16/97 (16.5%) | No dose-volume relationship found. | 1,7               | (n/a: 2–6)                   | 2                           |
| Poorvu [16]        | 1. Peritoneum + Colon | 1. Possible location of small bowel excluding solid organs & retroperitoneal structures. 2. Peritoneum (as above) plus asc & desc colon | CTCAE v4.0 Gr > 3 | 3/46 (6.5%) | No dose-volume relationship found. | 1,7               | (n/a: 2–6)                   | 2                           |
| Guerrero-Urbano [8] | Bowel loops | Loops from recto-sigmoid junction to 2 cm above PTV | RTOG Gr ≥ 2 = diarrhoea; LENT-SOMA consistency & frequency- worst grade | 21/79 (26%) | V40, V45, V60 and bowel volume of > 450 cc had both higher RTOG & LENT-SOMA diarrhoea. Constraints suggested: V40 < 124 cc, V45 < 71 cc, V60 < 0.5 cc for RTOG<gr 2 | 1,7               | (n/a: 2–3)                   | 1                           |
| McDonald [9]       | Bowel loops | Loops from recto-sigmoid junction to 2 cm above PTV | RTOG Gr ≥ 1 | 7/47 (14.9%) | Constraints for < 25% ≥ gr2 toxicity: V30 < 178 cc; V53 < 163 cc; V40 < 151 cc; V45 < 139 cc; V50 < 127 cc; V55 < 115 cc; V60 < 98 cc; V65 < 40 cc | 1,7, 2           | (n/a: 2–3)                   | 2                           |
| Chopra [11]        | Small bowel | 2 cm above target, individual small bowel loops (uneven how differentiated from large bowel) | CTCAE v3.0 Gr3+ | 9/71 (12.6%) | V15 associated with ≥ gr3 toxicity. Recommend V15 < 275 cc, V30 < 190 cc, V40 < 150 cc reduces Gr3 toxicity from 23.6 to 5.6%. | 1,4, 6           | (n/a: 2,3)                    | 2                           |
| Isohashi [10]      | Small bowel | Bowel loops remaining after exclusion of large bowel loops | RTOG/EORTC Gr ≥ 2 | 16/97 (16.5%) | V40 best predictor of late toxicity; Recommend V40 < 340 ml to reduce toxicity from 46.2 to 8.7% | 1,4, 6, 7        | (n/a: 2,3)                    | 2                           |
| Lind [12]          | Small bowel | All visible small bowel in small pelvic cavity to caudal part of sacroiliac joints | Defecation into clothing without warning > 1 in last 6 months | 63/519 (12.1%) | Mean dose>50Gy to small bowel or sigmoid or anal sphincter region associated with symptom (findings for individual organs not clarified) | 1, 7              | (n/a: 2,3)                    | 1,2, 3                      |
| Adkison [34]       | Small bowel | Not clearly defined | CTCAE v3.0 Gr1 and Gr2 | Gr1 16/53 (30%); Gr2 4/53 (8%) | No dose-volume relationship with V30–V60 small bowel | 1 (n/a: 2–6)       | None                         |                             |
| Fokdal [14]        | Small bowel | Opacified & unopacified small intestine loops (outer contour) | LENT-SOMA G1–4 | Symptom specific | No dose-volume relationship found. | 1,7               | (n/a: 2–6)                   | 1,2, 3                      |
faecal incontinence and 1 of faecal urgency, as summarised in Table 5. There was relative consistency in the recommended Dmean constraints between 40-47Gy, despite the OARs being defined slightly differently.

Other dose volume histogram (DVH) and dose-surface histogram (DSH) parameters

Many other DVH parameters of the anal canal were found to be important, including Dmin [23], Dmax, Dmedian [14], V40 [24], V65 [21] and V90% dose [25]; these were all in individual findings with little corroboration between studies. Vordermark et al. also found that the treatment field border was important, with those with a lower border 2 mm below ischial tuberosities more likely to have severe incontinence compared with 5 mm above the ischial tuberosities.

Buettner et al. [20] also examined incontinence using dose surface maps (DSM) for the anal canal. They found the mean dose to the anal surface and the lateral extent of the DSM to be most correlated with subjective sphincter toxicity. They recommend 45Gy for surface-based mean-dose to the anal canal to reduce toxicity.

Anal sphincter muscles

Smeenk et al. [26] related dose to individual sphincter muscles to urgency, frequency and incontinence. To reduce urgency and incontinence to below 5% they recommended a mean dose <30Gy to internal anal sphincter, <10Gy to the external sphincter, <50Gy to puborectalis and <40Gy to the levator ani muscles.

Normal tissue complication probability (NTCP) modeling

Four studies detailed NTCP models for the anal canal [20, 27–29], three of fitting data to a Lyman-Kutcher-Burman (LKB) model. Buettner et al. identified mean-dose anal canal parameters related to grade 2 RTOG toxicity, and Peeters et al. looked at anal wall parameters in relation to faecal incontinence, as detailed in Table 4. Peeters et al. further modified their model to incorporate a previous history of abdominal surgery and found this improved the model fit, suggesting a decreased radiation tolerance for patients with this risk factor. Thor et al. [29] proposed LKB models for pain, mucus and faecal leakage, although their findings are difficult to use practically as within their study they use data from two different centres, where each toxicity is defined differently between centres. Mavroidis et al.

Table 3 Whole bowel and small bowel studies – significant findings and quality assessment (Continued)

| Author           | OAR studied | OAR defined                                      | Toxicity definition                  | Pts with toxicity | Significant findings                                                                 | Statistical criteria met (1–7) | Endpoint criteria met (1–3) |
|------------------|-------------|--------------------------------------------------|--------------------------------------|-------------------|---------------------------------------------------------------------------------------|-------------------------------|----------------------------|
| Fonteyne [17]    | Small bowel | Not clearly defined                              | RTOG and “RILIT” Gr1 & Gr2           | Gr1 112/ 241 (46%), Gr2 32/ 241(13%) | No dose-volume relationship found                                                   | 1, (n/a 2–6)                  | 1,2                        |
| Poorvu [16]      | Small bowel | Opacified & non-opacified small bowel loops       | CTCAE v4.0 Gr3+                      | 3/46 (6.5%)       | No dose-volume relationship found                                                   | 1,7, (n/a 2–6)                | 2                          |
| Huang [15]       | Duodenum    | Duodenal bulb to ligament of Treitz               | CTCAE v4.0 Gr ≥ 3                    | 8/46 (17.4%)      | With a V25 > 45% toxicity rates increase from 8 to 48%                               | 1,4,6,7, (n/a 2,3)             | 2                          |
| Kelly [13]       | Duodenum    | Gastric pylorus until end of duodenum 3 cm past midline | CTCAE v4.0 Gr ≥ 2                    | 20/106 (18.9%)    | With a V55 > 1 cc toxicity rates increase from 9 to 47%                               | 1,4,6,7, (n/a 2,3)             | 2                          |
| Verma [30]       | Duodenum    | From gastric outlet through transverse portion of duodenum (ascending portion excluded) | RTOG, all grades                      | 9 /105 (8.6%)     | With a V55 > 15 cc toxicity rates increase from 7.4 to 48.6%                         | 1,4,6,7, (n/a 2,3)             | 2                          |
| Poorvu [16]      | Duodenal segments | D1 segment: bulblike shape & origin beyond gastric pylorus. Transitions between 2nd & 3rd segments was lateral border of IVC; Between 3rd & 4th was medial border of aorta | CTCAE v4.0 Gr ≥ 3 | 3/46 (6.5%) | No dose-volume relationship found with duodenum                                          | 1,7, (n/a 2–6)                | 2                          |

Abbreviations: Pts Patients, OAR Organs at risk, RT Radiotherapy, Gr Grade, CTCAE Common terminology criteria for adverse events, RTOG Radiation therapy oncology group, LENT-SOMA Late Effects of Normal Tissue – Subjective Objective Management Analytical, RILIT Radiation induced late intestinal toxicity, EORTC European Organisation for Research and Treatment of Cancer, vs Volume receiving x Gy, AUC Area under curve
Table 4: Large Bowel studies - details and quality assessment

| Author            | OAR studied        | OAR defined                                    | Toxicity definition                                                                 | Pts with toxicity | Significant findings                                                                 | Quality Assessment                                                                 |
|-------------------|--------------------|-----------------------------------------------|-------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Chopra [11]       | Large bowel        | 2 cm above target, individual loops of large bowel (unclear how differentiated from small bowel) | CTCAE v3.0 Gr ≥ 3                                                                   | 9/71 (12.6%)      | V15 associated with ≥ gr 3 toxicity. Constraints: V15 < 250 cc, V30 < 100 cc, V40 < 90 cc to reduce toxicity from 26.7 to 5.4% | 1, 4, 6 (n/a 2.3)                                                                 |
| Isohashi [10]     | Large bowel        | Single loop continuing from end of sigmoid to ascending colon | RTOG/EORTC, Gr ≥ 2                                                                 | 16/97 (16.5%)     | No constraint found for large bowel                                                                                                    | 1, 7 (n/a 2–6)                                                                 |
| Fonteyne [17]     | Sigmoid colon      | Where rectum sweeps anteriorly to one slice above aortic bifurcation | RTOG and “RILIT” Gr 1 and 2                                                        | Gr 1112/241 (46%), Gr 2 32/241 (13%). | V40 associated with gr1 diarrhoea & blood loss. Constraints: V40 < 10%, V30 < 16% to avoid gr1–2 diarrhoea | 1, 7 (n/a 3)                                                                 |
| Mouttet-Audouard  [6] | Sigmoid colon     | Anterior curvature of sigmoid colon to anterior abdominal wall  | CTCAE v4.0 Gr1–3 diarrhoea and “whole digestive toxicity”                           | 8/37 (21.6%)      | ‘Whole late digestive toxicity’ associated with V30–40. No specific constraints.      | 1, 7 (n/a 2–6)                                                                 |
| Lind [12]         | Sigmoid colon      | From where rectum deviates from its mid-position to where it turns cranially in left abdomen connecting to colon descendens | Defecation into clothing without warning > 1 in last 6 months                      | 63/519 (12.1%)    | Mean dose>50Gy to small bowel or sigmoid or anal sphincter region associated with symptom (findings for individual organs not clarified) | 1, 7 (n/a 2–6)                                                                 |
| al-Abany [18]     | Anal sphincter region | Caudal 3 cm of the rectum from anal verge (including filling) | Own questionnaire; Faecal leakage >2X/week                                          | 9/65 (13.8%)      | Increased risk with mean dose of 45-55Gy. Constraints: V35 < 60%, V40 < 40% associated with no risk of faecal leakage. | 1, 7 (n/a 2.3)                                                                 |
| Alsadius [19]     | Anal sphincter region | Caudal part of large bowel, from end of rectal ampulla where bowel no longer had visible content or air. | Own questionnaire; Faecal leakage >once per month                                   | 51/403 (12.7%)    | Dmean<40Gy reduces risk from 17 to 4%.                                                                                                   | 1, 2,4,7 (n/a 3)                                                                |
| Fokdal [14]       | Anal canal         | Outer contour of the structure extending from anal verge 2 cm cranially | LENT SOMA score                                                                     | Urge: 27/71 (38%); Incontinence: 21/71 (30%) | Urgency related to Dmed> 33.8: increases toxicity 31 to 47% Incontinence related to Dmax> 33.8 increases 14 to 44% | 1, 2,4,5,7 (n/a 3)                                                                |
| Vordermark [23]   | Anal canal         | Anal verge to the section below visible rectal lumen, corresponding to the upper border of the levator ani muscle | “Solid soiling” (Severe incontinence) Own continence questionnaire                  | 6/44 (14%)        | Severe incontinence - associated with Dmin (23.1Gy) related to portals extending 2 mm below ischial tuberosities (compared with 5 mm above) | 1, 7 (n/a 2–3)                                                                 |
| Koper [25]        | Anal canal         | Caudal 3 cm of the intestine                    | RTOG gr1 + 2; Plus symptom questionnaire.                                           | 141/248 (57%)     | D90% (=54.9Gy) to associated with ≥ gr1 rectal toxicity                               | 1, 7 (n/a 2–6)                                                                 |
| Taussky [37]      | Anal canal         | Most distal 2-3 cm of rectum                   | 10 questions from UCLA-PCI, FACT-P & EORTC QLQ-PR2S                                | Unclear           | no relation with anal canal DVH found                                                                                                     | 7 (N/a: 2–3)                                                                  |
| Buettner [20]     | Anal canal         | Caudal 3 cm of rectum                          | Common grading                                                                      | 57/388 (14.7%)    | DSH data: Toxicity correlated with dose to anal surface:                                                                                   | 1,3,6,7 (n/a 2)                                                                 |
Table 4  Large Bowel studies - details and quality assessment (Continued)

| Author          | OAR studied   | OAR defined                                                                 | Toxicity definition                                                                 | Pts with toxicity          | Significant findings                                                                 | Statistical considerations met (1–7) | Endpoint considerations met (1–3) |
|-----------------|---------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------|--------------------------------------|----------------------------------|
| Peeters [21]    | Anal wall     | Wall of caudal 3 cm of anorectum (method described)                          | RTOG/EORTC ≥ gr 2 and ≥ gr 3 Plus incontinence pad use>2x/wk.                        | 32/368 (7%)                | Dmean increase from 19Gy to 52Gy increased gr2 toxicity: 16 to 31%. V65 & Dmean most significant for incontinence. Dmean increase by 33Gy increased incontinence by 12% | 1,2,4,6,7 (n/a 3)                     | 1,2                              |
| Mavroidis [27]  | Anal sphincter region | Musculature layer around the rectal aperture, 3 cm caudal from anal verge | Own questionnaire                                                                    | faecal leakage 19/65 (29%); blood/mucus 22/65 (34%) | Relative seriality NTCP model of anal sphincter for incontinence, blood/mucus. Parameters for incontinence: D50 = 70.2Gy, γ = 1.22, s = 0.35. Parameters for blood/mucus: D50 = 74.0Gy, γ = 0.75, s ≈ 0 | 1, 3, 5, 6, 7 (n/a 2)                     | 1,3                              |
| Peeters [28]    | Anal canal wall | Wall of caudal 3 cm of anorectum (method described)                         | Incontinence requiring pad use>2x/wk;                                               | 63/519 (12.1%)             | Mean dose>50Gy to small bowel or sigmoid or anal sphincter region associated with this symptom (findings for individual organs not clarified) | 1,7 (n/a 2.3)                        | 1,2,3                            |
| Smeenk [26]     | Anal sphincter muscles | Individual muscles defined (Internal anal sphincter (IAS), external anal sphincter (EAS), puborectalis & levator ani) | Frequency, Urgency, Incontinence                                                   | 21/48 (44%)                | For urgency: Anal wall Dmean<38Gy risk < 15%, >38Gy risk is 62%                          | 1,4,7 (n/a 2,3,5,6)                    | 1,3                              |
| Smeenk [22]     | Anal wall     | Continuation of rectal wall from anal verge to slice below lowest slice with a rectal balloon | Frequency, urgency, incontinence                                                   | 72%                        | Anal wall V40 > 65% associated with chronic toxicity.                                   | 1,5 (n/a 2.3)                        | 2,3                              |
| Lind [12]       | Anal sphincter region | Inner muscle layer of the sphincter up to anal verge | Defecation into clothing without warning > 1 in last 6 months                      | 5 LKB models proposed for anal sphincter doses. Low anal sphincter dose associated with faecal leakage and pain. High anal sphincter dose associated with leakage. | 1,3,6 (n/a 2)                        | 1,2,3                            |
| Yeoh [24]       | Anal wall     | From anorectal junction (not clearly defined)                               | LENT-SOMA total score                                                              | 72%                        | Anal wall V40 > 65% associated with chronic toxicity.                                   | 1,5 (n/a 2.3)                        | 2,3                              |
| Thor [29]       | Anal sphincter | Anal canal, inner and outer sphincter (not clearly defined)               | Questionnaire of 19 questions in 4 domains: pain urgency, mucus & incontinence.     | 5 LKB models proposed for anal sphincter doses. Low anal sphincter dose associated with faecal leakage and pain. High anal sphincter dose associated with leakage. | 1,3,6 (n/a 2)                        | 1,2,3                            |
| Ebert [35]      | Anal Canal    | Caudal 3 cm of anorectum                                                   | LENT-SOMA – 8 symptoms                                                              | Specific to each symptom  | Bleeding associated with >40Gy, proctitis with 36-63Gy, frequency with 8-85Gy, urgency and tenesmus with | 1,5,7 (n/a 2)                        | 1,2,3                            |
modelled dose to the anal sphincter region for ‘faecal leakage’ and ‘blood or phlegm’ in stools using the relative seriality NTCP model. They recommended a reduction in the biologically effective uniform dose (EUD) to anal sphincter < 40–45Gy may significantly reduce toxicity.

Quality assessment
Statistical criteria
Most studies provided information on basic statistical data (29/30) and gave clear definitions of OARs (24/30). Constraints were derived in 16 papers, with associated complication rates stated in 12 papers. Goodness-of-fit was reported in 6 studies, with discriminator statistics reported in 10 papers. For the 4 papers with NTCP models all provided parameter estimates with standard error.

Endpoint criteria
Overall toxicity grades rather than individual symptoms were assessed in 13 of 30 studies, with patient-reported outcomes used in 14 studies (13 of which were studies of the anal canal). 21 of the studies looked at co-morbidity to assess its contribution to late toxicity and this was taken into account in multivariate analyses if thought to be associated.

Discussion
We have systematically reviewed the currently published literature on dose-volume constraints for late bowel toxicity after pelvic radiotherapy, excluding the rectum. We identified 30 studies including 5136 patients. A key finding was consistent dose-volume constraints defined for the anal canal from five studies. For whole bowel loops, small bowel, duodenum, large bowel and sigmoid dose-volume constraints were derived in individual studies, however there was limited validation of these findings in other studies examining the same component of bowel.

Of all the components of bowel studied, most data were available in the 16 studies examining the anal canal or anal sphincter region, and these studies were most conclusive. Statistical and endpoint measures recommended by QUANTEC were met much more frequently in these studies, data of which originated mainly from prostate clinical trials. Fifteen of these sixteen studies used individual symptoms reported by patients rather than an overall toxicity score.

These studies clearly indicate a relationship between dose-volume parameters to the anal canal and faecal incontinence. Dmean was the most significant parameter in five different studies, with a range of doses between 40-47Gy found. From the available data we recommend a constraint Dmean of <40Gy (in 2Gy fractions) to the anal canal to be included in clinical protocols in order to limit late bowel toxicity, in particular faecal incontinence.

For other components of bowel, the evidence was far less conclusive, as the findings of single studies were not corroborated with others. Possible reasons could be

| Study | No of pts | OAR studied | OAR defined | Toxicity definition | Pts with toxicity | Significant findings | Statistical considerations met (1–7) | Endpoint considerations met (1–3) |
|-------|-----------|-------------|-------------|--------------------|------------------|---------------------|--------------------------------------|----------------------------------|
| Al-albany [18] | 65 | Anal sphincter region | Region | Incontinence >2x/week | 43.2 | 8% | 52% |
| Al-sadius [19] | 403 | Anal canal | Canal | Incontinence > 1x/month | 40 | 5.2% | 21% |
| Buettner [20] | 388 | Anal sphincter region | Region | Incontinence: moderate/severe (gr2) | 47, though <30Gy ideal | 5% (approx; read from graph) |
| Smeenk [22] | 36 | Anal canal | Wall | Urgency present | 41.8 | 15% | 62% |
| Peeters [21] | 641 | Anal canal | Wall | Incontinence requiring pad >2x/week | No constraint specified | 16% at 19Gy | 31% at 52Gy |

Abbreviations: Pts Patients, OAR Organs at risk, RT Radiotherapy, Gr Grade, CTCAE Common terminology criteria for adverse events, RTOG Radiation therapy oncology group, LENT-SOMA Late Effects of Normal Tissue – Subjective Objective Management Analytical, RILIT Radiation induced late intestinal toxicity, EORTC European Organisation for Research and Treatment of Cancer, Vx Volume receiving x Gy, AUC Area under curve, Dmean Mean dose, Dmax Maximal dose, DVH Dose volume histogram, DSH Dose surface histogram, NTCP Normal Tissue Complication Probability, LKB Lyman Kutcher Burman.
For acute bowel toxicity QUANTEC have suggested two constraints: $V_{45} < 195\, \text{cc}$ for peritoneal cavity, and $V_{15} < 120\, \text{cc}$ for small bowel loops. The QUANTEC authors suggest these constraints may be applicable for late bowel toxicity. Some consistency is seen to QUANTEC recommendations within this review with Chopra et al. [11] finding $V_{15}$ small bowel loops to be important on multivariate analysis, although their recommended constraint was much higher at $V_{15} < 275\, \text{cc}$.

For peritoneal cavity, the findings of the studies reviewed do not corroborate with QUANTEC. Three studies found no correlation of peritoneal cavity doses with late toxicity, and the two positive studies found that in fact lower doses to peritoneal cavity of $V_{20}$ and $V_{10–30}$ [6, 31] were predictive of late toxicity. It would be important to validate the significance of these low doses in terms of late toxicity given the increased use of volumetric arc therapy (VMAT) techniques in recent years, where lower dose bath to a larger area of normal tissue is seen, the significance of which is currently not understood.

Strengths of this systematic review are the broad inclusivity of the search, with the studies included having patients with different tumour types, radiotherapy techniques, fractionations, and concurrent treatments. A similar approach was used in key papers such as the Emami et al. data [32], as well as the QUANTEC papers [3, 4], where bowel constraints were sought from studies with gynaecological, rectal, prostate and pancreatic cancers. A potential limitation of this is that some of these treatment factors may influence late toxicity (e.g. use of concurrent systemic agents, or hypofractionation). Although it is expected that individual authors may account for these factors statistically this may not have always been done and may explain partly the inconsistent results found.

Despite attempting to be as inclusive as possible we may have missed those studies not in English, and from grey literature currently unpublished. Studies involving SBRT were excluded given the questionable validity of the linear quadratic model with extreme hypofractionation thus making radiobiological comparisons difficult [33].

Quality assessment based on the QUANTEC-defined criteria added much value to this review, highlighting that many researchers do not report or consider the endpoint or statistical criteria, and further that those that do adhere to these criteria appear to have more conclusive findings.

Conclusions
We recommend the use of $D_{\text{mean}}$ to the anal canal of $<40\, \text{Gy}$ in pelvic radiotherapy protocols as a constraint to reduce the development of late bowel toxicity, in particular faecal incontinence.
Other important organs at risk to consider are whole bowel loops, small bowel, duodenum, large bowel and sigmoid colon and constraints for these OARS are noted in this review. However, clear recommendations for these organs cannot be made, due to lack of correlation between studies. Validation of the constraints found within this systematic review for these OARS with independent data sets would be an important next step. If validated these constraints could be used clinically in prospective patients, and also as a relevant benchmark to assess the likely impact of advanced radiotherapy techniques on late toxicity. Future studies should consider the quality criteria recommended by QUANTEC.

Abbreviations
Cc: Cubic centimetres; CTCAE: Common Terminology Criteria Adverse Events; Dmean: Mean Dose; DSH: Dose Surface Histogram; DVM: Dose Volume Histogram; EUD: Equivalent Uniform Dose; Gy: Gray; LKB: Lyman-Kutcher Burman; OAR: Organ at Risk; QUANTEC: Quantitative Analysis of Normal Tissue Effects in the Clinic; RTOG: Radiation Therapy Oncology Group; VMAT: Volumetric Modulated Arc Therapy; Vx Gy: Volume receiving x Gray

Acknowledgements
Not applicable.

Funding
This work was supported by Velindre Cancer Centre Charitable Funds, and Cancer Research Wales.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions
BC performed all systematic searching. RJ and EH screened all abstracts, and validated these constraints could be used clinically in prospective patients, and also as a relevant benchmark to assess the likely impact of advanced radiotherapy techniques on late toxicity. Future studies should consider the quality criteria recommended by QUANTEC.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Clinical Oncology, Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff CF14 2TL, UK. 2 Department of Clinical Oncology, Addenbrookes’ Hospital, Box 193, Cambridge CB2 0QQ, UK. 3 Cancer Research Wales Library, Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff CF14 2TL, UK. 4 School of Medicine, Institute of Cancer and Genetics, Cardiff University, Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff CF14 2TL, UK.

Received: 7 May 2018 Accepted: 27 March 2019

References
1. Benton B, Norton C, Lindsay JO, Dolan S, Andreyev HJ. Can nurses manage gastrointestinal symptoms arising from pelvic radiation disease? Clin Oncol (R Coll Radiol). 2011;23(8):538–51.
2. Andreyev HJ. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol). 2007;19(10):790–9.
3. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S123–9.
4. Kavanagh BD, Fan CC, Dawson LA, Das SK, Li YA, Ten Haken RK, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S101–7.
5. Jackson A, Marks LB, Bentzen SM, Eisebruch A, Yorke ED, Ten Haken RK, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S155–60.
6. Mouret-Audouard R, LaCroix G, Rasch E, Kramer A, Le Tinier F, Reynaert N, et al. What is the normal tissues morbidity following helical intensity modulated radiation treatment for cervical cancer? Radiother Oncol. 2015;115(3):386–91.
7. Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, et al. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(4):1389–96.
8. Guerrero Urbano T, Khoo V, Staffurth J, Norman A, Buffa F, Jackson A, et al. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol). 2010;22(3):236–44.
9. McDonald F, Waters R, Bullford S, Hall E, James N, Huddart RA. Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol (R Coll Radiol). 2015;27(1):22–9.
10. Isohashi F, Yoshioka Y, Mabuchi S, Konishi K, Koizumi M, Takahashi Y, et al. Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):28–34.
11. Chopra S, Dora T, Chinnacharyam AN, Thomas B, Kannan S, Engineer R, et al. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys. 2014;88(3):630–5.
12. Lind H, Alevronta E, Steinke G, Waldenstrom AC, Nyberg T, Olsson C, et al. Defecation into clothing without forewarning and mean radiation dose to bowel and anal-sphincter among gynecological cancer survivors. Acta Oncol. 2016;55(11):1285–93.
13. Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, et al. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):143–9.
14. Fordal L, Honore H, Hoyer M, van der Maase H. Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiat Oncol. 2005;4(2):203–10.
15. Huang J, Roberson JM, Ye H, Yan D. Dose-volume analysis of predictors for gastrointestinal toxicity after radiotherapy and concurrent full-dose gemcitabine for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):1220–5.
16. Poznuk PD, Sadow CA, Townamchai K, Damaro AL, Viswanathan AN. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Int J Radiat Oncol Biol Phys. 2013;85(5):1262–8.
17. Fonteyne V, De Neve W, Villiers G, De Wagger C, De Meelereer G. Late radiotherapy-induced lower intestinal toxicity (RLIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol. 2007;84(2):156–63.
18. al-Albany M, Helgason AR, Cronqvist AK, Lind B, Mavroidis P, Wesslau P, et al. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys. 2005;61(4):1035–44.
19. Alasadus D, Hedelin M, Lundstedt D, Pettersson N, Wilderang U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84(2):e151–5.
20. Buetnner F, Bullford S, Webb S, Sydes MR, Deanaley DP, Partridge M. The dose-response of the anal sphincter region—an analysis of data from the MRC RT01 trial. Radiat Oncol. 2012;7(3):347–52.
21. Peeters ST, Lebesque JV, Heemersbergen WD, van Putten WL, Slot A, Dieiwart MF, et al. Localized volume effects for late rectal and anal toxicity after...
radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64(4):1151–61.

22. Smeenk RJ, Hopman WP, Hoffmann AL, van Lin EN, Kaanders JH. Differences in radiation dosimetry and anorectal function testing imply that anorectal symptoms may arise from different anatomic substrates. Int J Radiat Oncol Biol Phys. 2012;82(1):145–52.

23. Vordermark D, Schwab M, Ness-Dourdoumas R, Sailer M, Flentje M, Koelbl O. Association of anorectal dose-volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate. Radiat Oncol. 2003;69(2):209–14.

24. Yeoh EK, Krol R, Dhillon VS, Botten R, Di Matteo A, Butters J, et al. Predictors of radiation-induced gastrointestinal morbidity: a prospective, longitudinal study following radiotherapy for carcinoma of the prostate. Acta Oncol. 2016;55(5):604–10.

25. Koper PC, Jansen P, van Putten W, van Os M, Wijnmaalen AJ, Lebesque JV, et al. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol. 2004;73(1):1–9.

26. Smeenk RJ, Hoffmann AL, Hopman WP, van Lin EN, Kaanders JH. Dose-effect relationships for individual pelvic floor muscles and anorectal complaints after prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(2):636–44.

27. Mavroidis P, al-Abany M, Helgason AR, Agren Cronqvist AK, Wensall P, Lind H, et al. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol. 2005;181(5):293–306.

28. Peeters ST, Hoogeman MS, Heemsbergen WD, Hart AA, Koper PC, Lebesque JV. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys. 2006;66(1):11–19.

29. Thor M, Olsson CE, Öh HH, Petersen SE, Aaldisius D, Bentzen SM, et al. Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. Acta Oncol. 2015;54(9):1226–34.

30. Verma J, Sulman EP, Jhingran A, Tucker SL, Rauch GM, Eifel PJ, et al. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the Para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):357–62.

31. Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):763–72.

32. Emami B, Foo K, Haworth A, Guillford SI, Kennedy A, Joseph DJ, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.

33. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18(4):240–3.

34. Adkison JB, Mclaffie DR, Bentzen SM, Patel RR, Khuntia D, Peterieit DG, et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):184–90.

35. Ebert MA, Foo K, Haworth A, Guillford SI, Kennedy A, Joseph DJ, et al. Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: analysis of data from the RADAR prostate radiation therapy trial. Int J Radiat Oncol Biol Phys. 2015;91(3):595–603.

36. Green GL, Zhang J, Ransinghani N, Asawi S. Dose-volume relationship of acute and late small bowel toxicity from radiation therapy for prostate cancer: a veterans affairs study. J Radiat Oncol. 2015;4:411–5.

37. Taussky D, Schneider U, Rousson V, Pescia R. Patient-reported toxicity correlated to dose-volume histograms of the rectum in radiotherapy of the prostate. Am J Clin Oncol. 2003;26(3):144–9.